Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study

被引：0

作者：

Arnold, Douglas ^{[1
,2
]}

Freeman, Leorah ^{[3
]}

Hartung, Hans-Peter ^{[4
,5
,6
,7
]}

Montalban, Xavier ^{[8
]}

Cohen, Jeffrey ^{[9
]}

Bar-Or, Amit ^{[10
,11
]}

Steinman, Lawrence ^{[12
]}

DeLuca, John ^{[13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[16
]}

机构：

[1] NeuroRx Res, Montreal, PQ, Canada

[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[3] Univ Texas Austin, Dell Med Sch, Austin, TX USA

[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany

[5] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[6] Med Univ Vienna, Dept Neurol, Vienna, Austria

[7] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic

[8] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[9] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

[10] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA USA

[11] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA

[12] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA USA

[13] Kessler Fdn, West Orange, NJ USA

[14] Rutgers New Jersey Med Sch, Dept Phys Med Rehabil & Neurol Neurosci, Newark, NJ USA

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1661/518

引用

页码：1050 / 1051

页数：2

共 50 条

[1] Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
Arnold, Douglas L.
Freeman, Leorah
Hartung, Hans-Peter
Montalban, Xavier
Cohen, Jeffrey A.
Bar-Or, Amit
Steinman, Lawrence
DeLuca, John
Cheng, Chun-Yen
Riolo, Jon V.
Silva, Diego
Pachai, Chahin
Cree, Bruce A. C.
NEUROLOGY, 2023, 100 (17)
[2] Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis
Arnold, D. L.
Freeman, L.
Hartung, H. -P.
Xavier Montalban, X.
Cohen, J. A.
Bar-Or, A.
Steinman, L.
DeLuca, J.
Cheng, C. -Y.
Riolo, J. V.
Silva, D.
Pachai, C.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 377 - 378
[3] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
Steinman, L.
Comi, G.
Bar-Or, A.
Selmaj, K. W.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Janjua, A.
Huang, V.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
[4] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Hartung, Hans-Peter
Steinman, Lawrence
Bar-Or, Amit
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Harris, Sarah
Reardon, Jennifer
Thorpe, Andrew
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
[5] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Minton, N.
Afsari, S.
Shi, F.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
[6] Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-or, A.
Arnold, D. L.
Hartung, H-P
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Hetzer, J.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 473 - 474
[7] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, E. K.
Krakovich, A.
Sheffield, J. K.
Cheng, C. -Y.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
[8] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
Selmaj, K.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D.
Hartung, H. P.
Montalban, X.
Havrdova, E.
Sheffield, J.
Chen, T.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
[9] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Arnold, D. L.
Hartung, H. -P.
Montalban, X.
Havrdova, K.
Hoogerheyde, J.
Afsari, S.
Sheffield, J. K.
Shi, F.
Minton, N.
Silva, D.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
[10] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
Selmaj, K. W.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H. P.
Montalban, X.
Havrdova, E. K.
Sheffield, J. K.
Thorpe, A.
Riolo, J. V.
Krakovich, A.
Cheng, C. Y.
Kappos, L.
Cohen, J. A.
Cree, B. A. C.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326

← 1 2 3 4 5 →